OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM

An open label, dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of OriCAR-017 in R/RMM

Trial Details

NCT ID
NCT06182696
Phase
PHASE1 / PHASE2
Sponsor
OriCell Therapeutics Co., Ltd.
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • OriCAR-017
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142
  • Beijing, China|39.9075,116.39723
  • Nanjing, China|32.06167,118.77778
  • Shanghai, China|31.22222,121.45806
  • Wuhan, China|30.58333,114.26667

Key Eligibility Criteria

  • Diagnosis of R/RMM according to the IMWG criteria;
  • Expected survival period is \>12 weeks;
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 or 2 at the time of ICF signature;
  • The expression of GPRC5D in bone marrow plasma cells membrane is more than 20% by flow cytometry and/or immunohistochemistry, multiple myeloma with…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →